Tier 3 — preclinical

Balance between DNA repair, LINE1 suppression and lifespan in mice with SIRT6 Serine 10 phosphorylation site mutations

Zhihui Zhang, Matthew Simon, Yuan Liang, Alexander Tyshkovskiy, Mila Kaplan, Victoria Paige, Seyed Ali Biashad, Vadim Gladyshev, Andrei Seluanov, Vera Gorbunova
bioRxiv 2026 Preprint

Bibliography

PubMed
PMID 41676543

Study snapshot

DesignGenetically engineered mouse study comparing phospho-null S10A and phosphomimetic S10E SIRT6 mutants with wild-type controls.
ModelSIRT6 Ser10 mutant mice and associated molecular assays.
SampleMouse lifespan cohorts; exact group sizes reported in the preprint.
InterventionConstitutive SIRT6 Ser10 phospho-null or phosphomimetic mutation.
DurationLifespan study.
EndpointsLifespan; DNA repair capacity; LINE1 expression; SIRT6 recruitment to DNA damage

What the study showed, in plain terms

A 2026 mouse preprint found that a phosphomimetic SIRT6 S10E mutation improved DNA repair yet increased LINE1 expression and shortened male lifespan. The result is an important warning against treating a single SIRT6 function such as DNA repair as automatically equivalent to better longevity.

Key findings

S10E enhanced DNA repair but weakened LINE1 control and reduced male lifespan relative to wild-type and S10A mice, suggesting balanced SIRT6 functions matter more than maximizing one repair output.

What this study can and cannot tell us

Preprint; genetically engineered mice rather than pharmacological SIRT6 activation; sex-specific lifespan effect; does not establish effects of fucoidan or other consumer SIRT6 activators.

Citation network

Articles citing this research paper

4 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified